China Resources Group (06628.HK) announced that the updated research data of the G series for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (TranStar102) with Osemitamab (TST001) combined with nal-IRI and CAPOX continues to show promising efficacy since its announcement at ASCO 2024.

The study results show that in patients with known levels of CLDN18.2 and PD-L1 expression, the median progression-free survival (mPFS) for patients with high/medium CLDN18.2 expression is 14.2 months, with a confirmed objective response rate of 68%. The majority of patients had PD-L1 CPS < 5.

As of the data cutoff date, due to the limited number of events, the median overall survival has not been reached in the overall population (82 patients) of the G series. The 12-month survival rate for the overall population is 73.8% (95% CI: 62.0-82.4%).